Gut microbiota and their metabolites in cardiovascular disease
- PMID: 33642219
- DOI: 10.1016/j.beem.2021.101492
Gut microbiota and their metabolites in cardiovascular disease
Abstract
The gut microbiome affects the development and progress of various types of disease such as obesity, diabetes, atherosclerosis and arterial thrombosis. Gut microbiome derived metabolites have been established to be predictive of arterial thrombosis in epidemiological studies. In these studies atherosclerosis and prothrombotic effect cannot be distinguished but preclinical studies show gut derived metabolites can induce platelet hyperreactivity and increase thrombotic potential. Gut commensals can also influence platelets through serotonin synthesis and may enhance Von Willebrand factor production. The effects on secondary haemostasis are less studied. In antiphospholipid syndrome, a thrombotic auto-immune disorder, autoreactive T cells and antibodies cross-react with auto-antigen mimicking peptides from gut commensals which appears to contribute to the pathophysiology. This review focusses on the prothrombotic effect of the gut microbiome and aims to provide insight into its influence on thromboembolic disease and the haemostatic system.
Keywords: dysbiosis; gastrointestinal microbiome; haemostasis; stroke; thrombosis.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest S.M. reports grants and personal fees from Bayer, BMS Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Portola, GSK and Aspen and personal fees from Sanofi. The other authors declare no potential conflict of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources